The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress).
 
Tom Stinchcombe
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; EMD Serono; Foundation Medicine; Genentech/Roche; Janssen Oncology; Lilly; Medtronic; Novartis; Pfizer; Puma Biotechnology; Regeneron; Takeda
Research Funding - Advaxis (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Genentech/Roche (Inst); Regeneron (Inst); Takeda (Inst)
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Abbvie; Advaxis; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Asymmetric Therapeutics; Boston Biomedical; ChemoID; Clovis Oncology; Deciphera; Eisai; Elevar Therapeutics; Geistlich Pharma; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Immunomedics; Incyte; Iovance Biotherapeutics; Iovance Biotherapeutics; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Nucana; Oncomed; Oncoquest; Oncosec; Perthera; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Senti Biosciences; Starton Therapeutics; Takeda; Tarveda Therapeutics; TESARO/GSK; Vascular Biogenics; Vavotar Life Sciences; Vigeo Therapeutics
Consulting or Advisory Role - Abbvie; Advaxis; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Asymmetric Therapeutics; Boston Biomedical; Chemocare; ChemoCare; ChemoID; Clovis Oncology; Deciphera; Eisai; Geistlich Pharma; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Immunomedics; Incyte; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Nucana; Oncomed; Oncoquest; Oncosec; Perthera; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Senti Biosciences; Sorrento Therapeutics; Sorrento Therapeutics; Takeda; Tarveda Therapeutics; TESARO/GSK; Vascular Biogenics; Vavotar Life Sciences; Vigeo Therapeutics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
Alicia Frances Clare Okines
Stock and Other Ownership Interests - AstraZeneca (I)
Consulting or Advisory Role - Roche/Genentech
Speakers' Bureau - Seagen
Research Funding - Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; LEO Pharma
 
Paula R Pohlmann
Leadership - Immunonet BioSciences
Stock and Other Ownership Interests - Immunonet BioSciences
Honoraria - Dava Oncology; Frontiers Media; OncLive/MJH Life Sciences
Consulting or Advisory Role - Bolt Biotherapeutics; Caris Life Sciences; HERON; Immunonet BioSciences; Juniper Pharmaceuticals; OncoPlex Diagnostics; Personalized Cancer Therapy; Pfizer; Puma Biotechnology; Sirtex Medical
Speakers' Bureau - Genentech/Roche
Research Funding - Advanced Cancer Therapeutics (Inst); Bolt Biotherapeutics (Inst); Byondis (Inst); Caris Centers of Excellence (Inst); Caris Centers of Excellence (Inst); Cascadian Therapeutics (Inst); Fabre-Kramer (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Pfizer (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Patent application; United States Patent no. 8,486,413.; United States Patent no. 8,501,417; United States Patent no. 9,023,362; United States Patent no. 9,745,377
 
Evan Y. Yu
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Bayer; Clovis Oncology; Exelixis; Janssen; Merck; Myovant Sciences; Sanofi
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Celularity; Daiichi Sankyo/UCB Japan; Eisai; Eisai; Exact Sciences; Foundation Medicine; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Treos Bio
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - AstraZeneca; Exelixis; Lilly; Merck (Inst); Pancreatic Cancer Action Network
 
Yoshiaki Nakamura
Research Funding - Chugai Pharma (Inst); Genomedia (Inst); Guardant Health (Inst); Taiho Pharmaceutical (Inst)
 
David M. O'Malley
Consulting or Advisory Role - Abbvie; Agenus; Ambry Genetics; AstraZeneca; Clovis Oncology; Eisai; Elevar Therapeutics; Genelux; Genentech/Roche; GlaxoSmithKline; GOG Foundation; Immunogen; Iovance Biotherapeutics; Janssen Oncology; Leap Therapeutics; Marker Therapeutics; Myriad Genetics; Novartis; Novocure; OncoQuest; Regeneron; Rubius Therapeutics; Rubius Therapeutics; Seagen; Sorrento Therapeutics; Tarveda Therapeutics; Tesaro; Translational Genomics Research Institute
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Agenus (Inst); Ajinomoto (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Eisai (Inst); Eisai (Inst); EMD Serono (Inst); Ergomed (Inst); Genentech/Roche (Inst); Genmab (Inst); Immunogen (Inst); Immunogen (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Leap Therapeutics (Inst); Merck (Inst); Mersana (Inst); PharmaMar (Inst); Regeneron (Inst); Seagen (Inst); Tesaro (Inst); TRACON Pharma (Inst)
 
Vicky Kang
Employment - Seagen
Stock and Other Ownership Interests - Myovant Sciences
 
Luke N. Walker
Employment - Seagen; Seagen
Stock and Other Ownership Interests - Seagen
Patents, Royalties, Other Intellectual Property - patents as inventor via status as employee of Seattle Genetics
Travel, Accommodations, Expenses - Seagen
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech